Canonical product evidence map
Retatrutide Evidence Map
A source-linked map separating peer-reviewed human trials, trial registries, sponsor status reports, mechanism studies and regulatory context for retatrutide.
- 10
- unique source records
- 3
- research types
- 2022–2026
- source-year range
Evidence distribution
See the source mix before reading the conclusions.
A large record count does not imply mature human evidence. The model and source type determine which question a record can answer.
Research type
Study model
Source-linked records
10 records connected to Retatrutide
Records are deduplicated by canonical source URL and keep their model, type and evidence-tier labels visible.
FDA concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration. Content current through May 31, 2026.
TRIUMPH-1 sponsor-reported topline results
Eli Lilly and Company. May 21, 2026. Sponsor news release; not a full peer-reviewed report.
TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results
Eli Lilly and Company. July 23, 2026. Sponsor news release; detailed publication pending.
ZEPBOUND (tirzepatide) prescribing information
U.S. FDA. Revised 2026. NDA 217806.
What to know about retatrutide
Eli Lilly and Company. Medically reviewed; updated July 2026.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. N Engl J Med. 2023;389:514–526. PMID 37366315.
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. N Engl J Med. 2022;387:205–216. PMID 35658024.
A Study of Retatrutide in Participants Who Have Obesity or Overweight
ClinicalTrials.gov record NCT04881760.
TRIUMPH-1 ClinicalTrials.gov record
Protocol and current study-status record.
Google guidance on people-first content and substantive date changes
Official Google Search Central guidance cited for the editorial-update statement.
Evidence boundary
A source set is not a clinical recommendation.
- Human, animal, in-vitro, analytical, registry and regulatory records remain separate evidence categories.
- A published intervention or approved finished medicine does not verify the identity or quality of a catalog research lot.
- Record inclusion does not mean every finding has been independently replicated or applies outside its stated population and model.
Continue researching